🎯 #ESMO2026 2º day Rapid oral GU non-prostate session. @Uro_Oncologist presented the HRQL of EV-304 periop MIBC!!
EV +pembro was not associated with a clinically meaningful detriment in general HRQoL or cystectomy-specific HRQoL!! @OncoAlert @myESMO @GuardConsortium @DrChoueiri @tompowles1 @urotoday @PGrivasMDPhD
120 浏览 · 7 赞 · 5 转发 · 3 回复
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.org- Daniel Castellano@cdanicas
@OncoAlert @myESMO @urotoday @tompowles1 @GuardConsortium @PGrivasMDPhD @Maroto5Pablo 🎯 #ESMO2026 Periop Tislelizumab with Neoadjuvant Disitamab Vedotin in High-Risk Upper Tract Urothelial Carcinoma in HER2 + pts WUTSUP-02 Trial ORR 81.0% with pCR of 28.2% @OncoAlert @myESMO @PGrivasMDPhD @tompowles1 @urotoday @GuardConsortium
- Daniel Castellano@cdanicas
@OncoAlert @myESMO @urotoday @tompowles1 @GuardConsortium @PGrivasMDPhD 🎯 #ESMO2026 Long-term follow-up analysis from EV-103 cohorts Dose Escalation, A and K ! @Maroto5Pablo In 1L unfit mUC with long mOS @OncoAlert @myESMO @urotoday @tompowles1 @GuardConsortium
- Daniel Castellano@cdanicas
🎯 Update of the GUARD-01 trial periop MIBC with Disitamab + gem for HER-2 + pts! 62.5% pCR (4 cycles > 3 cycles) Pending to GUARD-02 ph 3 trial including Disitamab + toripalimab cohort!! @OncoAlert @myESMO @urotoday @tompowles1
来源：Daniel Castellano · x.com